The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]
- PMID: 28496341
- PMCID: PMC5422532
- DOI: 10.2147/OTT.S140498
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]
Abstract
[This retracts the article on p. 1735 in vol. 10, PMID: 28356761.].
Retraction of
-
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.Onco Targets Ther. 2017 Mar 21;10:1735-1742. doi: 10.2147/OTT.S132806. eCollection 2017. Onco Targets Ther. 2017. Retraction in: Onco Targets Ther. 2017 May 04;10:2425. doi: 10.2147/OTT.S140498. PMID: 28356761 Free PMC article. Retracted.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
